Regencell Bioscience Holdings Ltd is an early-stage bioscience company that focuses on research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, specifically ADHD and ASD. Its goal is to save and improve the lives of patients, their families and caregivers and become a market leader for the natural and holistic treatment globally. The company operates and manages its business as a single segment - in the research and development of the company's product candidates.
Last trade$4.62
Day change-$0.10 (-2.12%)
Day range$4.36 – $4.89
Volume72,908
Market cap$2.34B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for RGC.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for RGC.
Recent news
Company coverage with links to the original publishers.
Class action lawsuits have been filed against LKQ Corporation, Regencell Bioscience Holdings Limited, and Globant S.A. The complaints allege that defendants made materially false and misleading statements and failed to disclose material adverse facts about their businesses. LKQ faced issues with FinishMaster losing major customers post-acquisition, Regencell was vulnerable to market manipulation, and Globant faced decreasing demand in Latin America with frozen wages.
Rosen Law Firm has announced securities class action lawsuits against FS KKR Capital Corp. (FSK), Regencell Bioscience Holdings Limited (RGC), and Microsoft (MSFT). The FSK lawsuit alleges the company made false statements regarding portfolio restructuring effectiveness, investment valuations, and distribution strategy durability. Investors with losses exceeding $100K are encouraged to join the class action before the July 6, 2026 deadline for FSK and June 23, 2026 for RGC.
Rosen Law Firm is encouraging investors with losses exceeding $100,000 in Regencell Bioscience Holdings Limited, FS KKR Capital Corp., and Microsoft to join securities class action lawsuits. The firm has set a June 23, 2026 deadline for lead plaintiff claims. The lawsuits allege that defendants made false or misleading statements regarding market manipulation vulnerabilities and regulatory risks.
Faruqi & Faruqi, LLP is reminding investors in Regencell Bioscience Holdings Limited (RGC) of the June 23, 2026 deadline to seek lead plaintiff status in a federal securities class action. The lawsuit alleges that Regencell and its executives made false and misleading statements by concealing the company's vulnerability to market manipulation and the resulting regulatory risks. The DOJ investigation was disclosed on October 31, 2025, causing RGC's share price to fall 18.56% on November 3, 2025.
Rosen Law Firm has issued multiple securities class action deadline alerts for investors. The primary case involves Sportradar Group AG (SRAD), where investors who purchased shares between November 7, 2024 and April 21, 2026 may be entitled to compensation. The lawsuit alleges that Sportradar made false statements about compliance and worked with black-market gambling operators while claiming strict regulatory adherence. The lead plaintiff deadline is July 17, 2026. Similar deadline alerts were also issued for FS KKR Capital Corp. (FSK) and Regencell Bioscience Holdings Limited (RGC).
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Feb 15, 2018
$0.0058
Feb 26, 2018
recurring
Dec 1, 2017
$0.0058
Dec 15, 2017
recurring
Aug 31, 2017
$0.0058
Sep 15, 2017
recurring
Jun 1, 2017
$0.0058
Jun 15, 2017
recurring
Mar 1, 2017
$0.0058
Mar 15, 2017
recurring
Stock splits
Historical share-structure events and their execution dates.